We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.41 | -8.32% | 4.52 | 4.52 | 4.63 | 5.045 | 4.725 | 4.93 | 4,846,191 | 00:59:41 |
GAITHERSBURG, Md., March 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will provide a corporate update and report its fourth quarter and full year 2017 financial and operating results following the close of U.S. financial markets on Wednesday, March 14, 2018.
Conference call and webcast details are as follows: | |
Date: | March 14, 2018 |
Time: | 5:00 p.m. U.S. Eastern Time (ET) |
Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
Passcode: | 6472939 |
Webcast: | www.novavax.com, "Investors"/ "Events" |
Conference call and webcast replay: | |
Dates: | Starting at 8:00 p.m. ET, March 14, 2018 until |
9:00 p.m. ET March 21, 2018 | |
Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
Passcode: | 6472939 |
Webcast: | www.novavax.com, "Investors"/ "Events", until June 14, 2018 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Our RSV and influenza nanoparticle vaccine candidates are Novavax' most advanced clinical programs and are at the forefront of the Company's efforts to improve global health. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investors
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions